Adenosine deaminase deficiency

Adenosine deaminase deficiency
ICD-10	D81.3
ICD-9	279.2
OMIM	102700
DiseasesDB	260

WikiDoc Resources for Adenosine deaminase deficiency
Articles
Most recent articles on Adenosine deaminase deficiency Most cited articles on Adenosine deaminase deficiency Review articles on Adenosine deaminase deficiency Articles on Adenosine deaminase deficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Adenosine deaminase deficiency Images of Adenosine deaminase deficiency Photos of Adenosine deaminase deficiency Podcasts & MP3s on Adenosine deaminase deficiency Videos on Adenosine deaminase deficiency
Evidence Based Medicine
Cochrane Collaboration on Adenosine deaminase deficiency Bandolier on Adenosine deaminase deficiency TRIP on Adenosine deaminase deficiency
Clinical Trials
Ongoing Trials on Adenosine deaminase deficiency at Clinical Trials.gov Trial results on Adenosine deaminase deficiency Clinical Trials on Adenosine deaminase deficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Adenosine deaminase deficiency NICE Guidance on Adenosine deaminase deficiency NHS PRODIGY Guidance FDA on Adenosine deaminase deficiency CDC on Adenosine deaminase deficiency
Books
Books on Adenosine deaminase deficiency
News
Adenosine deaminase deficiency in the news Be alerted to news on Adenosine deaminase deficiency News trends on Adenosine deaminase deficiency
Commentary
Blogs on Adenosine deaminase deficiency
Definitions
Definitions of Adenosine deaminase deficiency
Patient Resources / Community
Patient resources on Adenosine deaminase deficiency Discussion groups on Adenosine deaminase deficiency Patient Handouts on Adenosine deaminase deficiency Directions to Hospitals Treating Adenosine deaminase deficiency Risk calculators and risk factors for Adenosine deaminase deficiency
Healthcare Provider Resources
Symptoms of Adenosine deaminase deficiency Causes & Risk Factors for Adenosine deaminase deficiency Diagnostic studies for Adenosine deaminase deficiency Treatment of Adenosine deaminase deficiency
Continuing Medical Education (CME)
CME Programs on Adenosine deaminase deficiency
International
Adenosine deaminase deficiency en Espanol Adenosine deaminase deficiency en Francais
Business
Adenosine deaminase deficiency in the Marketplace Patents on Adenosine deaminase deficiency
Experimental / Informatics
List of terms related to Adenosine deaminase deficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Adenosine deaminase deficiency, or ADA deficiency, is an inherited immunodeficiency syndrome accounting for about 25% of all cases of severe combined immunodeficiency (SCID).

This disease is due to a lack of the enzyme adenosine deaminase coded for by a gene on chromosome 20. There is an accumulation of dATP, which causes an increase in S-adenosylhomocysteine; both substances are toxic to immature lymphoid cells, so fail to reach maturity. As a result, the immune system of the afflicted person is severely compromised or completely lacking.

The enzyme adenosine deaminase is important for purine metabolism.

Historical Perspective

Adenosine deaminase (ADA) deficiency was first discovered by Dr. Eloise Giblett in 1972, when she received samples from a patient with severe combined immunodeficiency (SCID) that was a candidate for bone marrow transplantation; examination of blood samples presented that the patients have no ADA activity. With discovering a second case with ADA deficiency and immunedeficiency, ADA deficiency was the first immunodeficiency in which the specific molecular defect was described.

Classification

There is no established system for the classification of adenosine deaminase deficiency.

Pathophysiology

Adenosine deaminase (ADA) is an ubiquitous enzyme found in all cells, It catalyzes the deamination of adenosine and deoxyadenosine to inosine and deoxyinosine. ADA deficiency is caused by mutations in the ADA1 gene at 20q13.11. In the absence of functional ADA, there is an intracellular accumulation of adenosine and deoxyadenosine which leads a buildup of dATP and prevent de novo synthesis of nucleotides and deoxynucleotides in all cells, and inhibits ribonucleotide reductase and prevents DNA synthesis.

In addition, deoxyadenosine irreversibly binds to and inhibits S-adenosylhomocysteine hydrolase, a rise in S-adenosylhomocysteine since the enzyme adenosine deaminase is important in the purine salvage pathway; both substances are toxic to immature lymphocytes, which thus fail to mature. which also contributes to abnormal DNA synthesis.

ADA-deficient individuals typically have severely reduced numbers of T, B, and natural killer (NK) cells.

Causes

Adenosine deaminase deficiency is a disorder arising from mutation in the ADA1 gene at 20q13.11.

Differentiating [Disease] from Other Diseases

Adenosine deaminase deficiency must be differentiated from other diseases that cause clinical features of severe combined immunodeficiency , and complete DiGeorge syndrome. Although DiGeorge syndrome is associated with facial and cardiac anomalies which are not seen with ADA deficiency.

Epidemiology and Demographics

TThe incidence of ADA deficiency is approximately 1 per 200,000 livebirths worldwide. It accounts for nearly one-third of all cases of autosomal recessive severe combined immunodeficiency (SCID) and approximately 15 percent of all cases of SCID.

Risk Factors

There are no established risk factors for adenosine deaminase deficiency.

Screening

preferably, SCID can be diagnosed in a newborn before the beginning of infections, with one well-documented example by screening of T-cell–receptor excision circles(TRECs). Since the goal of newborn screening is to detect treatable disorders that are threatening to life or long-term health before they become symptomatic and prompt treatment of SCID may notably reduce mortality and morbidity among patients. Infants with SCID without reconstitution of a functioning immune system generally die of overwhelming infection by one year of age.

T cell receptor excision circles (TRECs) as a biomarker of naïve T cells, is a sensitive and specific, as well as cost effective, method for SCID newborn screening.

Treatment

Medical Therapy

• bone marrow transplant
• gene therapy (efforts halted due to increased incidence of leukemia)
• ADA enzyme in PEG vehicle
• Stem Cell Therapy(still in the experimental stage)

The first gene therapy to combat this disease was performed by Dr. W. French Anderson on a 4yr old girl, Ashanti DeSilva, in 14 September 1990 at the National Institute of Health, Bethesda, Maryland, U.S.A.

The therapy performed was the first successful case of gene therapy.

Primary Prevention

===Secondary Prevention

External links

• Gene Therapy: A Brief History: [2]